PETER J O'DWYER

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. ncbi request reprint Priorities in colorectal cancer research: recommendations from the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups
    PETER J O'DWYER
    Coalition of Cancer Cooperative Groups, Philadelphia, PA, USA
    J Clin Oncol 25:2313-21. 2007
  2. ncbi request reprint The present and future of angiogenesis-directed treatments of colorectal cancer
    PETER J O'DWYER
    Abramson Cancer Center, University of Pennsylvania, 51 N 39th Street, MAB 103, Philadelphia, Pennsylvania 19104, USA
    Oncologist 11:992-8. 2006
  3. ncbi request reprint Additive interaction of oxaliplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines results from inhibition of nuclear factor kappaB signaling
    Tatiana V Rakitina
    Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Cancer Res 63:8600-5. 2003
  4. ncbi request reprint Phase I trial of combretastatin a-4 phosphate with carboplatin
    Joshua H Bilenker
    University of Pennsylvania Cancer Center, University of the Sciences in Philadelphia, Philadelphia, PA 19104, USA
    Clin Cancer Res 11:1527-33. 2005
  5. ncbi request reprint Phase I and pharmacokinetic trial of the novel taxane BMS-184476 administered as a 1-hour intravenous infusion in combination with cisplatin every 21 days
    Weijing Sun
    Abrahmson Family Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Clin Cancer Res 9:5221-7. 2003
  6. doi request reprint Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study
    Keith T Flaherty
    Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
    Cancer Chemother Pharmacol 68:1111-8. 2011
  7. doi request reprint MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib
    Hyunseon Christine Kang
    Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
    AJR Am J Roentgenol 200:120-6. 2013
  8. ncbi request reprint Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies
    Joshua H Bilenker
    Abramson Family Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
    Cancer Chemother Pharmacol 53:357-60. 2004
  9. ncbi request reprint Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancy
    Keith T Flaherty
    Abramson Cancer Center, University of Pennsylvania, Medical Arts Buildingm Suite 103, 39th and Market Streets, Philadelphia, PA 19104, USA
    Cancer Chemother Pharmacol 52:217-22. 2003
  10. doi request reprint Two phase I studies of concurrent radiation therapy with continuous-infusion 5-fluorouracil plus epirubicin, and either cisplatin or irinotecan for locally advanced upper gastrointestinal adenocarcinomas
    Weijing Sun
    Abramson Cancer Center of University of Pennsylvania, Philadelphia, PA, 19104 4283, USA
    Cancer Chemother Pharmacol 67:621-7. 2011

Detail Information

Publications46

  1. ncbi request reprint Priorities in colorectal cancer research: recommendations from the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups
    PETER J O'DWYER
    Coalition of Cancer Cooperative Groups, Philadelphia, PA, USA
    J Clin Oncol 25:2313-21. 2007
    ..The implementation of biology-directed laboratory investigations, both in association with ongoing clinical trials and as a separate developmental strategy for targeted therapies, is supported as the route to individualized therapy...
  2. ncbi request reprint The present and future of angiogenesis-directed treatments of colorectal cancer
    PETER J O'DWYER
    Abramson Cancer Center, University of Pennsylvania, 51 N 39th Street, MAB 103, Philadelphia, Pennsylvania 19104, USA
    Oncologist 11:992-8. 2006
    ..We hypothesize that bevacizumab may potentiate the efficacy of cytotoxics not solely by alterations of tumor interstitial pressure but also by promoting sensitivity to proapoptotic signals consequent upon nutrient and oxygen withdrawal...
  3. ncbi request reprint Additive interaction of oxaliplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines results from inhibition of nuclear factor kappaB signaling
    Tatiana V Rakitina
    Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Cancer Res 63:8600-5. 2003
    ..These data support an interaction between 17-AAG and components of the NF-kappaB pathway in the modulation of oxaliplatin sensitivity in colon cancer cells...
  4. ncbi request reprint Phase I trial of combretastatin a-4 phosphate with carboplatin
    Joshua H Bilenker
    University of Pennsylvania Cancer Center, University of the Sciences in Philadelphia, Philadelphia, PA 19104, USA
    Clin Cancer Res 11:1527-33. 2005
    ..Preclinical evidence of synergy led to a phase I trial employing combretastatin A-4 phosphate (CA4P), a novel tubulin-binding antivascular drug, in combination with carboplatin...
  5. ncbi request reprint Phase I and pharmacokinetic trial of the novel taxane BMS-184476 administered as a 1-hour intravenous infusion in combination with cisplatin every 21 days
    Weijing Sun
    Abrahmson Family Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Clin Cancer Res 9:5221-7. 2003
    ..2 +/- 4.5 h, respectively. BMS-184476 60 at mg/m(2) with cisplatin at 75 mg/m(2) with appropriate supportive therapy is the dose recommended for further evaluation...
  6. doi request reprint Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study
    Keith T Flaherty
    Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
    Cancer Chemother Pharmacol 68:1111-8. 2011
    ....
  7. doi request reprint MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib
    Hyunseon Christine Kang
    Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
    AJR Am J Roentgenol 200:120-6. 2013
    ..The purpose of this study was to examine early MRI changes in renal cell carcinoma (RCC) treated with the antiangiogenic agent sorafenib and to identify MRI biomarkers of RCC response to sorafenib...
  8. ncbi request reprint Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies
    Joshua H Bilenker
    Abramson Family Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
    Cancer Chemother Pharmacol 53:357-60. 2004
    ..To determine the maximum tolerated dose and dose-limiting toxicities (DLTs) of ZD9331 in combination with cisplatin in patients with refractory solid tumors and to describe any preliminary antitumor activity associated with this regimen...
  9. ncbi request reprint Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancy
    Keith T Flaherty
    Abramson Cancer Center, University of Pennsylvania, Medical Arts Buildingm Suite 103, 39th and Market Streets, Philadelphia, PA 19104, USA
    Cancer Chemother Pharmacol 52:217-22. 2003
    ..We performed a phase I trial of carboplatin and paclitaxel in combination with gemcitabine in order to determine the tolerability of this triplet...
  10. doi request reprint Two phase I studies of concurrent radiation therapy with continuous-infusion 5-fluorouracil plus epirubicin, and either cisplatin or irinotecan for locally advanced upper gastrointestinal adenocarcinomas
    Weijing Sun
    Abramson Cancer Center of University of Pennsylvania, Philadelphia, PA, 19104 4283, USA
    Cancer Chemother Pharmacol 67:621-7. 2011
    ..Epirubicin, cisplatin, and irinotecan are active cytotoxic chemotherapy agents in UGI cancers...
  11. doi request reprint Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma
    Weijing Sun
    Abramson Cancer Center, Department of Medicine, Hematology Oncology Division, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Cancer 117:3187-92. 2011
    ..This phase 2 study was designed to determine the efficacy and toxicity of the combination of bevacizumab, capecitabine, and oxaliplatin in patients with advanced unresectable and untransplantable HCC...
  12. doi request reprint Autophagy inhibition sensitizes colon cancer cells to antiangiogenic and cytotoxic therapy
    Muthu Selvakumaran
    Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania 19014, USA
    Clin Cancer Res 19:2995-3007. 2013
    ..We examined the effect of inhibiting autophagy on hypoxic colon cancer cells in vitro and on bevacizumab- and oxaliplatin-treated mouse xenografts in vivo...
  13. doi request reprint A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel
    Keith T Flaherty
    The Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Clin Cancer Res 14:4836-42. 2008
    ..Pharmacokinetic analyses were done for sorafenib on days 2 and 19 of cycle 1 and for paclitaxel on day 1 of cycles 1 and 2. Pretreatment tumor samples from 17 melanoma patients were analyzed for BRAF mutations...
  14. ncbi request reprint Mechanisms of hypertension associated with BAY 43-9006
    Maria Luisa Veronese
    Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Clin Oncol 24:1363-9. 2006
    ..The current study investigated the incidence, severity, and mechanism of blood pressure (BP) elevation in patients treated with BAY 43-9006...
  15. ncbi request reprint Phase I and pharmacokinetic trial of the proapoptotic sulindac analog CP-461 in patients with advanced cancer
    Weijing Sun
    University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania 19104, USA
    Clin Cancer Res 8:3100-4. 2002
    ..Four patients exhibited disease stability after two cycles of treatment. CP-461 is minimally toxic at doses up to 800 mg/day when administered p.o. on a twice-daily schedule...
  16. doi request reprint Disruption of signaling through SEK1 and MKK7 yields differential responses in hypoxic colon cancer cells treated with oxaliplatin
    Irina A Vasilevskaya
    Abramson Family Cancer Center, University of Pennsylvania, 1020 BRB II III, 421 Curie Blvd, Philadelphia, PA 19104, USA
    Mol Pharmacol 74:246-54. 2008
    ..These data support a positive contribution of MKK7/JNK to oxaliplatin cytotoxicity and identify SEK1 as a potential target for reversal of hypoxic resistance to oxaliplatin...
  17. ncbi request reprint Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200
    Bruce J Giantonio
    University of Pennsylvania, Philadelphia, PA, USA
    J Clin Oncol 25:1539-44. 2007
    ..This study was conducted to determine the effect of bevacizumab (at 10 mg/kg) on survival duration for oxaliplatin-based chemotherapy in patients with previously treated metastatic colorectal cancer...
  18. pmc Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203
    Weijing Sun
    Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104 4283, USA
    J Clin Oncol 28:2947-51. 2010
    ..A phase II study was conducted to determine the efficacy and toxicity of combined sorafenib, docetaxel, and cisplatin in patients with metastatic or advanced adenocarcinoma of stomach or gastroesophageal junction (GEJ)...
  19. ncbi request reprint A validated liquid chromatography/tandem mass spectrometry assay for cis-amminedichloro(2-methylpyridine)platinum(II) in human plasma ultrafiltrate
    Tomoyuki Oe
    Center for Cancer Pharmacology, Department of Pharmacology, University of Pennsylvania, Philadelphia 19104 6160, USA
    Anal Chem 74:591-9. 2002
    ..The method provided adequate sensitivity for the analysis of plasma ultrafiltrate samples from a phase II study in which ZD0473 was administered to patients as an intravenous infusion at a dose of 150 mg/m2...
  20. pmc Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis
    Muthu Selvakumaran
    Abramson Cancer Center, University of Pennsylvania, 1020 BRB II III, 421 Curie Blvd, Philadelphia, PA 19104, USA
    Biochem Pharmacol 75:627-38. 2008
    ..The induction of apoptosis by hypoxia may contribute to the benefits of such treatment in the clinical setting...
  21. pmc Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors
    Crystal S Denlinger
    Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Cancer Chemother Pharmacol 65:97-105. 2009
    ..Exploratory analyses of the impact of variability in uridine diphosphate glucuronosyltransferase 1A (UGT1A) genes on irinotecan metabolism and toxicity were conducted...
  22. pmc Phase II trial of sorafenib in advanced thyroid cancer
    Vandana Gupta-Abramson
    Developmental TherapeuticsProgram of the Abramson CancerCenter, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Clin Oncol 26:4714-9. 2008
    ....
  23. ncbi request reprint Reversal of cisplatin resistance in human ovarian cancer cell lines by a c-jun antisense oligodeoxynucleotide (ISIS 10582): evidence for the role of transcription factor overexpression in determining resistant phenotype
    Bin Pan
    University of Pennsylvania, Cancer Center, Philadelphia, PA 19104, USA
    Biochem Pharmacol 63:1699-707. 2002
    ..These data suggest that altered regulation of transcription factor expression contributes to the acquired resistance phenotype in these ovarian cancer cells, and provide a novel potential target for therapeutic intervention...
  24. doi request reprint Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer
    Keith T Flaherty
    Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA
    Clin Cancer Res 18:568-76. 2012
    ....
  25. doi request reprint Do phase 1 patients have greater needs for palliative care compared with other cancer patients?
    Esme Finlay
    Division of Hematology Oncology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Cancer 115:446-53. 2009
    ..The objectives of the current study were to define the palliative care needs of these patients and to determine whether their needs are greater than those of other cancer patients...
  26. ncbi request reprint Role of Jun and Jun kinase in resistance of cancer cells to therapy
    Irina Vasilevskaya
    University of Pennsylvania Cancer Center, 51 N 39th Street, MAB 103, Philadelphia, PA 19014, USA
    Drug Resist Updat 6:147-56. 2003
    ..This preliminary evidence suggests that c-jun may have a role in drug resistance, but additional work with patient tumor samples is required to validate the potential of the JNK pathway as a target...
  27. ncbi request reprint Epidermal growth factor receptor-targeted therapy in colorectal cancer
    PETER J O'DWYER
    University of Pennsylvania Cancer Center, Philadelphia, PA 19104, USA
    Semin Oncol 29:10-7. 2002
    ..Preclinical and clinical trials using these new therapeutic modalities appear promising in the treatment of colorectal cancer and are reviewed in this article...
  28. ncbi request reprint Current status of oxaliplatin in colorectal cancer
    PETER J O'DWYER
    University of Pennsylvania Cancer Center, Philadelphia, PA 19104, USA
    Semin Oncol 30:78-87. 2003
    ..Current efforts are directed toward individualizing therapy through predictive analyses of the targets and metabolic pathways of all three agents in pharmacogenetic and pharmacogenomic studies...
  29. ncbi request reprint Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance
    Jianguo Ma
    Department of Pharmacology, Fox Chase Cancer Center, 7701 Burholme Ave, Philadelphia, PA 19111, USA
    Biochem Pharmacol 63:1219-28. 2002
    ....
  30. ncbi request reprint Monoclonal antibodies in the treatment of colorectal cancer
    Maria Luisa Veronese
    Abramson Cancer Center, University of Pennsylvania, 51 N 39th St, MAB 103, Philadelphia, PA 19104, USA
    Eur J Cancer 40:1292-301. 2004
    ..Additional compounds are in earlier stages of development, and the future of this approach in solid tumours is promising...
  31. ncbi request reprint Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody
    Robert H Vonderheide
    Abramson Family Cancer Research Institute, Abramson Cancer Center, Division of Hematology Oncology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    J Clin Oncol 25:876-83. 2007
    ..CD40 is also expressed by solid tumors, but its engagement results in apoptosis. CP-870,893, a fully human and selective CD40 agonist monoclonal antibody (mAb), was tested for safety in a phase I dose-escalation study...
  32. ncbi request reprint Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma
    Keith T Flaherty
    Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Cancer Biol Ther 7:496-501. 2008
    ..Sorafenib is a novel RAF and VEGF receptor tyrosine kinase inhibitor. We conducted this study to (a) determine if sorafenib is anti-angiogenic, and (b) to relate anti-angiogenic effect to outcome...
  33. doi request reprint Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer
    Christine A Ciunci
    Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
    Cancer 120:77-85. 2014
    ..Therefore, a phase 1/pharmacodynamic trial of everolimus with cetuximab was performed...
  34. pmc The terrible choice: re-evaluating hospice eligibility criteria for cancer
    David J Casarett
    Center for Health Equity Research and Promotion, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, USA
    J Clin Oncol 27:953-9. 2009
    ..Our goal was to determine whether willingness to make this choice identifies patients with greater need for hospice services...
  35. ncbi request reprint Role of the AP-1 element and redox factor-1 (Ref-1) in mediating transcriptional induction of DT-diaphorase gene expression by oltipraz: a target for chemoprevention
    Kang Shen Yao
    University of Pennsylvania, 51 N 39th Street, MAB Suite 103, Philadelphia, PA 19104, USA
    Biochem Pharmacol 66:15-23. 2003
    ..These data suggest the importance of transcriptional activation mediated by AP-1 in the chemopreventive activity of oltipraz, and indicate that novel chemoprevention structures may be selected based upon agonist activity at this locus...
  36. ncbi request reprint Rhabdomyolysis from cytochrome p-450 interaction of ketoconazole and simvastatin in prostate cancer
    Haruka Itakura
    University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania 19104, USA
    J Urol 169:613. 2003
  37. pmc CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans
    Gregory L Beatty
    Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, 421 Curie Boulevard, Philadelphia, PA 19104, USA
    Science 331:1612-6. 2011
    ..Thus, cancer immune surveillance does not necessarily depend on therapy-induced T cells; rather, our findings demonstrate a CD40-dependent mechanism for targeting tumor stroma in the treatment of cancer...
  38. ncbi request reprint Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors
    Maria Luisa Veronese
    Division of Hematology Oncology, Abramson Cancer Center, University of Pennsylvania, 51 N 39th Street, MAB 103, Philadelphia, PA 19104, USA
    Cancer Chemother Pharmacol 55:497-501. 2005
    ..Preclinical studies indicate that CT-2103 has substantial antitumor efficacy in xenograft tumor models...
  39. doi request reprint How should we design supportive cancer care? The patient's perspective
    David Casarett
    University of Pennsylvania, 3615 Chestnut St, Philadelphia, PA 19104, USA
    J Clin Oncol 26:1296-301. 2008
    ..Although so-called open-access hospice programs and bridge programs are beginning to offer these services to patients who are still receiving treatment, it is not known whether they best meet patients' needs...
  40. ncbi request reprint Phase I and pharmacokinetic study of the cytotoxic ether lipid ilmofosine administered by weekly two-hour infusion in patients with advanced solid tumors
    Bruce J Giantonio
    Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Clin Cancer Res 10:1282-8. 2004
    ....
  41. pmc Inhibition of mutated, activated BRAF in metastatic melanoma
    Keith T Flaherty
    Abramson Cancer Center of the University of Pennsylvania, Philadelphia, USA
    N Engl J Med 363:809-19. 2010
    ..The identification of somatic mutations in the gene encoding the serine-threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test oncogene-targeted therapy for this disease...
  42. ncbi request reprint A phase I, dose escalation trial of ZD0473, a novel platinum analogue, in combination with gemcitabine
    Keith T Flaherty
    Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA 19104, USA
    Cancer Chemother Pharmacol 53:404-8. 2004
    ..In single-agent studies of ZD0473, myelosuppression was the predominant toxicity and responses wer observed...
  43. ncbi request reprint Determination of the platinum drug cis-amminedichloro(2-methylpyridine)platinum(II) in human urine by liquid chromatography-tandem mass spectrometry
    Tomoyuki Oe
    Center for Cancer Pharmacology, Department of Pharmacology, University of Pennsylvania, 1254 BRB II III, 421 Curie Boulevard, Philadelphia, PA 19104 6160, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 792:217-27. 2003
    ..Formation of the adduct was prevented by the addition of 50% (w/v) sodium chloride to the urine. The assay can be used to quantify intact ZD0473 in the urine of subjects dosed with this new platinum drug...
  44. ncbi request reprint 17-Allylamino-17-demethoxygeldanamycin overcomes TRAIL resistance in colon cancer cell lines
    Irina A Vasilevskaya
    University of Pennsylvania Cancer Center, 1020 BRB II III, 421 Curie Blvd, Philadelphia, PA 19104, USA
    Biochem Pharmacol 70:580-9. 2005
    ....
  45. ncbi request reprint Macrophage migration inhibitory factor is a determinant of hypoxia-induced apoptosis in colon cancer cell lines
    Kangshen Yao
    University of Pennsylvania, Philadelphia, PA 19104, USA
    Clin Cancer Res 11:7264-72. 2005
    ..We suggest that MIF expression in colorectal cancer may be a marker of susceptibility to therapies that may depend on induction of hypoxia, possibly including antiangiogenic therapy...
  46. ncbi request reprint Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow
    James P Stevenson
    University of Pennsylvania, 16 Penn Tower, 3400 Spruce St, Philadelphia, PA 19104, USA
    J Clin Oncol 21:4428-38. 2003
    ..The present study investigated escalating doses of CA4P administered intravenously to patients with advanced cancer...

Research Grants11

  1. Interaction of anti-angiogenic and cytotoxic therapies in colorectal cancer
    PETER O DWYER; Fiscal Year: 2009
    ..Improving patient care requires us to identify which patients will respond to these therapies, and to avoid unwanted effects and to investigate alternative approaches in those who will not. ..
  2. GENE EXPRESSION AND HYPOXIC CELL RESISTANCE
    PETER O DWYER; Fiscal Year: 2004
    ..It is expected that this work will yield novel targets for the reversal of hypoxic cell resistance in the clinic. ..
  3. MECHANISMS OF CHEMOPROTECTION BY OLTIPRAZ
    PETER O DWYER; Fiscal Year: 2003
    ..We will also screen a series of dithiolethione analogues for their ability to induce NER activity. The results of these studies will enable the design of more selective and less toxic chemopreventive agents. ..
  4. Interaction of anti-angiogenic and cytotoxic therapies in colorectal cancer
    PETER J O apos DWYER; Fiscal Year: 2010
    ..Improving patient care requires us to identify which patients will respond to these therapies, and to avoid unwanted effects and to investigate alternative approaches in those who will not. ..